SU931102A3 - Способ получени производных фенэтаноламина или их солей в форме рацемата или оптически-активного антипода - Google Patents
Способ получени производных фенэтаноламина или их солей в форме рацемата или оптически-активного антипода Download PDFInfo
- Publication number
- SU931102A3 SU931102A3 SU802977044A SU2977044A SU931102A3 SU 931102 A3 SU931102 A3 SU 931102A3 SU 802977044 A SU802977044 A SU 802977044A SU 2977044 A SU2977044 A SU 2977044A SU 931102 A3 SU931102 A3 SU 931102A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- salts
- racemate
- producing
- optically active
- phenethanolamine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
5 -1.1-диметил-З- Cf-MeTMflaMMHOKapGoнилфенил )-пропиламинхлорид с т.плГ21 220®С; К-(2-фенил-2-гидроксиэтил)-1 ,1-диметил-З(АДиметиламинокарбо / илфенил)-пропиламиноксалат С т.пл. 237-2 0°С. Пример 6. По методике примера 3 осуществл ют реакцию между 1,1-диметил-З- ((-аминокарбонилфенил -пропиламином и оптически активной окисью R-o-фторстирола, получа R-N-(2-)2-фтopфeнил{-гидpoкcиэтил)-1 ,1 -диметил-З- ( -аминокарбонилфенил )-пропиламин. Предлагаемые соединени способст вуют значительному увеличению актив ности средств лечени новообразований , используемых на мышах и хом ка зараженных имплантированными опухол ми . В типичном эксперименте такого рода лабораторные мыши заражались в результате подкожной имплантации опухолей ткани в периферийных част х тела. Первоначальный раз мер опухоли у каждого животного сос тавл л примерно 2 мм, затем раз мер опухоли измер лс периодически . В качестве типовых опухолевых систем имплантировались аденокарцинома-755 , штамм Эли Фаст бронхиоген ной карциномы и лимфосаркома. В качестве онкологических средств использовались цитоксан, 5-фторурацил , виндезин и другие. В качестве контрольных выбиралось 20-30 зараженных животных, получа1ших успо026 коительное нейтральное средство. Дл изучени воздействи на каждый из онкологических агентов бралось по 10 зараженных животных, получавших только онкологическое средство, и 10 других животных, получавш-их онкологическое средство нар ду с предлагаемым соединением. В таблице представлены результаты по комбинированной хемотерапии при лечении мышей, зараженных аденокарциномой , .представл щей собой опухоль груди у людей. Результаты,представленные в таблице,получены при введении в течение 28 дней нейтрального успокоительногрсредства , 6-меркаптопурина (бМР) с предлагаемым соединени-i ем: М-(2-фенил-2-гидроксиэтил-)-1,1 -диметил-З- (-гидроксифенил)-пропиламинобромидом (А), f1oлyчeнныe результаты выражены в виде среднего роста опухоли в мм , а также в виде числа животных, выживших после подобной обработки, дл каждой из групп. Измерени размеров опухолей проводились в те дни после имплантации опухоли, которые отмечены в таблице. Средний размер опухоли дл каждой из групп в соответствующий день приводитс в столбце I дл каждого из дней, в который проводилось измерение . В столбце II дл каждого из дней наблюдений приводитс количество выживших животных дл каждой испытуемой группы.
Как следует из приведенных данных, предлагаемые соединени вл ютс полезными с точки зрени усилени воздействи средств лечени новообразований и могут использоватьс в комбинации с известными онкологическими средствами дл лечени новообразований .
Claims (1)
- Формула изобретени Способ получени производных фенэтаноламина общей формулы/ i / л VCHCH NHC-CW/ -Yv УЯг(о СИ}
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92166878A | 1978-07-03 | 1978-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU931102A3 true SU931102A3 (ru) | 1982-05-23 |
Family
ID=25445786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU792786502A SU965351A3 (ru) | 1978-07-03 | 1979-07-02 | Способ получени гидрохлорида N-(2-фенил-2-гидроксиэтил)-1,1-диметил-3-(4-гидроксифенил)-пропиламина в виде рацемата или оптически активного изомера |
| SU802977044A SU931102A3 (ru) | 1978-07-03 | 1980-09-12 | Способ получени производных фенэтаноламина или их солей в форме рацемата или оптически-активного антипода |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU792786502A SU965351A3 (ru) | 1978-07-03 | 1979-07-02 | Способ получени гидрохлорида N-(2-фенил-2-гидроксиэтил)-1,1-диметил-3-(4-гидроксифенил)-пропиламина в виде рацемата или оптически активного изомера |
Country Status (33)
| Country | Link |
|---|---|
| EP (2) | EP0047536B1 (ru) |
| JP (1) | JPS559100A (ru) |
| AR (2) | AR222658A1 (ru) |
| AT (1) | AT370408B (ru) |
| AU (1) | AU521744B2 (ru) |
| BE (1) | BE877392A (ru) |
| BG (3) | BG40480A3 (ru) |
| CA (1) | CA1120058A (ru) |
| CH (1) | CH641759A5 (ru) |
| CS (2) | CS208660B2 (ru) |
| DD (1) | DD144763A5 (ru) |
| DK (1) | DK268579A (ru) |
| EG (1) | EG14400A (ru) |
| ES (2) | ES482153A1 (ru) |
| FI (1) | FI67686C (ru) |
| FR (1) | FR2430409A1 (ru) |
| GB (1) | GB2028800B (ru) |
| GR (1) | GR72546B (ru) |
| HK (1) | HK44087A (ru) |
| HU (1) | HU179170B (ru) |
| IE (1) | IE48436B1 (ru) |
| IL (1) | IL57670A (ru) |
| LU (1) | LU81456A1 (ru) |
| MX (1) | MX6160E (ru) |
| MY (1) | MY8500596A (ru) |
| NZ (1) | NZ190859A (ru) |
| PH (1) | PH15650A (ru) |
| PL (2) | PL123990B1 (ru) |
| PT (1) | PT69840A (ru) |
| RO (2) | RO77731A (ru) |
| SU (2) | SU965351A3 (ru) |
| YU (1) | YU154879A (ru) |
| ZA (1) | ZA793295B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2965655D1 (en) * | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| NL8105170A (nl) * | 1980-12-10 | 1982-07-01 | Thomae Gmbh Dr K | Nieuwe fenylalkylaminen, werkwijze ter bereiding daarvan en de toepassing daarvan als geneesmiddelen. |
| EP0068669A1 (en) * | 1981-06-20 | 1983-01-05 | Beecham Group Plc | Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application |
| CA1219865A (en) * | 1982-05-14 | 1987-03-31 | Leo Alig | Aziridine phenethanolamine derivatives |
| CA1258454A (en) * | 1982-08-10 | 1989-08-15 | Leo Alig | Phenethanolamines |
| EP0102213A1 (en) * | 1982-08-21 | 1984-03-07 | Beecham Group Plc | Ethanolamine derivatives, pharmaceutical compositions containing them, and processes for preparing them |
| EP0117647B1 (en) * | 1983-01-31 | 1988-08-17 | Eli Lilly And Company | Improvements in or relating to phenethanolamines |
| US4849453A (en) * | 1983-01-31 | 1989-07-18 | Eli Lilly And Company | Growth promotion |
| US4569801A (en) * | 1984-10-15 | 1986-02-11 | Eli Lilly And Company | Alkylsulfonamidophenylalkylamines |
| JPS62155213A (ja) * | 1985-12-20 | 1987-07-10 | イ−ライ・リリ−・アンド・カンパニ− | 腫瘍細胞崩壊剤 |
| EG18188A (en) * | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
| US5135955A (en) * | 1988-04-25 | 1992-08-04 | Eli Lilly And Company | Propanamine derivatives |
| US5051423A (en) * | 1988-07-13 | 1991-09-24 | Schering Ag | Derivatized alkanolamines as cardiovascular agents |
| US5541197A (en) * | 1994-04-26 | 1996-07-30 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| CN1073983C (zh) * | 1994-10-31 | 2001-10-31 | 中国科学院成都有机化学研究所 | 一种β－拟肾上腺素兴奋剂型饲料添加剂的合成方法 |
| EP1402890B1 (en) | 2001-06-08 | 2008-01-09 | Institute of Medicinal Molecular Design, Inc. | Sulfonamide derivatives |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6610530A (ru) * | 1966-07-27 | 1968-01-29 | ||
| BE757005A (fr) * | 1969-10-02 | 1971-04-02 | Bristol Myers Co | Phenethanolamines substituees et procede pour leur preparation |
| US3801631A (en) * | 1972-02-16 | 1974-04-02 | Mead Johnson & Co | 2'-hydroxy-5'-(1-hydroxy-2-(2-methyl-1-phenyl-2-propylamino)ethyl)meth-anesulfonanilide and its salts |
-
1979
- 1979-06-26 DK DK268579A patent/DK268579A/da not_active Application Discontinuation
- 1979-06-26 CA CA000330569A patent/CA1120058A/en not_active Expired
- 1979-06-26 IL IL57670A patent/IL57670A/xx unknown
- 1979-06-27 PH PH22700A patent/PH15650A/en unknown
- 1979-06-27 EG EG386/79A patent/EG14400A/xx active
- 1979-06-27 NZ NZ190859A patent/NZ190859A/en unknown
- 1979-06-28 YU YU01548/79A patent/YU154879A/xx unknown
- 1979-06-28 AU AU48488/79A patent/AU521744B2/en not_active Ceased
- 1979-06-28 PT PT69840A patent/PT69840A/pt unknown
- 1979-06-29 FR FR7916992A patent/FR2430409A1/fr active Granted
- 1979-06-29 HU HU79EI866A patent/HU179170B/hu unknown
- 1979-07-02 SU SU792786502A patent/SU965351A3/ru active
- 1979-07-02 RO RO7998011A patent/RO77731A/ro unknown
- 1979-07-02 BG BG7944165A patent/BG40480A3/xx unknown
- 1979-07-02 LU LU81456A patent/LU81456A1/xx unknown
- 1979-07-02 JP JP8489479A patent/JPS559100A/ja active Granted
- 1979-07-02 EP EP81109790A patent/EP0047536B1/en not_active Expired
- 1979-07-02 GB GB7922953A patent/GB2028800B/en not_active Expired
- 1979-07-02 MX MX798145U patent/MX6160E/es unknown
- 1979-07-02 RO RO105066A patent/RO83053B/ro unknown
- 1979-07-02 FI FI792080A patent/FI67686C/fi not_active IP Right Cessation
- 1979-07-02 EP EP79301282A patent/EP0007206B1/en not_active Expired
- 1979-07-02 BG BG7945919A patent/BG40481A3/xx unknown
- 1979-07-02 CS CS794630A patent/CS208660B2/cs unknown
- 1979-07-02 BE BE1/9443A patent/BE877392A/fr not_active IP Right Cessation
- 1979-07-02 BG BG7945920A patent/BG40482A3/xx unknown
- 1979-07-02 CH CH616479A patent/CH641759A5/fr not_active IP Right Cessation
- 1979-07-02 CS CS794630A patent/CS208661B2/cs unknown
- 1979-07-02 GR GR59488A patent/GR72546B/el unknown
- 1979-07-03 AR AR277165A patent/AR222658A1/es active
- 1979-07-03 AT AT0463979A patent/AT370408B/de not_active IP Right Cessation
- 1979-07-03 ZA ZA793295A patent/ZA793295B/xx unknown
- 1979-07-03 PL PL1979222867A patent/PL123990B1/pl unknown
- 1979-07-03 ES ES482153A patent/ES482153A1/es not_active Expired
- 1979-07-03 DD DD79214071A patent/DD144763A5/de unknown
- 1979-07-03 PL PL1979216810A patent/PL119783B1/pl unknown
- 1979-08-08 IE IE1231/79A patent/IE48436B1/en unknown
-
1980
- 1980-01-18 ES ES487847A patent/ES487847A0/es active Granted
- 1980-09-12 SU SU802977044A patent/SU931102A3/ru active
- 1980-10-06 AR AR282776A patent/AR222727A1/es active
-
1985
- 1985-12-30 MY MY596/85A patent/MY8500596A/xx unknown
-
1987
- 1987-06-04 HK HK440/87A patent/HK44087A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU931102A3 (ru) | Способ получени производных фенэтаноламина или их солей в форме рацемата или оптически-активного антипода | |
| US6617331B2 (en) | Purine inhibitors of protein kinases, G proteins and polymerases | |
| PT1121363E (pt) | Pirazole[3,4-d]pirimidin-4-onas substituidas na posicao 6, uteis como inibidores de cinase dependentes de ciclina | |
| GT199800113A (es) | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. | |
| CN102458410A (zh) | 治疗实体瘤的方法 | |
| JPS6330885B2 (ru) | ||
| Axelrad et al. | Responses evoked in mouse and rat SI cortex by vibrissa stimulation | |
| ATE33556T1 (de) | Adenosinderivate enthaltende pharmazeutische zusammensetzung fuer behandlung von tumoren. | |
| Bauer | A history of the discovery and clinical application of antiviral drugs | |
| ATE99931T1 (de) | Inhibitoren fuer zellenzuwachs und methoden fuer krebsbehandlung. | |
| Galdino da Rocha Pitta et al. | The evolution of drugs on schistosoma treatment: looking to the past to improve the future | |
| Knobloch et al. | Synthesis of hydrolysis-resistant pyridoxal 5′-phosphate analogs and their biochemical and X-ray crystallographic characterization with the pyridoxal phosphatase chronophin | |
| SE7705370L (sv) | 12-azaprostanoinsyror | |
| JP2015515496A5 (ru) | ||
| Ignarro et al. | Effects of prostaglandins on release of enzymes from lysosomes of pancreas, spleen and kidney cortex | |
| ES402567A1 (es) | Procedimiento para la produccion de aminofenil-cicloamidi- nas. | |
| DK429480A (da) | Phosphonohydroxyeddikesyre fremgangsmaader til fremstilling deraf samt anvendelse deraf som laegemiddel | |
| FR2426081A1 (fr) | Reactif d'oxydo-reduction pour un procede de desulfuration par voie humide et procede pour sa preparation | |
| Sherman et al. | Incorporation of P32 into trichloroacetic acid fractions of liver from irradiated and nonirradiated mice | |
| Goldberg | Mechanisms of neurotoxicity as studied in tissue culture systems | |
| Blohm et al. | Effects of N-allylnormorphine on cholinesterases | |
| Meister | Adenosinetriphosphatase activity of human serum | |
| Anderson et al. | Regression and differentiation of neuroblastoma tumors in mice treated with differentiating agents-prostaglandin E1 and a phosphodiesterase inhibitor, RO 20-1724 | |
| ES2194320T3 (es) | Sustancias naturales antivirales o antitumorales y uso de las mismas. | |
| Burger | Telomerase in cancer diagnosis and therapy: a clinical perspective |